Alector to Participate at Virtual Investor Conferences in September

Alector Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Alector to Present at the BTIG Virtual Biotechnology Conference 2020

Alector Announces Promising Preliminary Data from AL001 Phase 1b and Phase 2 Open-Label Long-Term Dosing Study of People with Frontotemporal Dementia

Alector Doses First Patient in Pivotal Phase 3 INFRONT-3 Trial Evaluating AL001 in Patients with Frontotemporal Dementia

Alector to Present Data from the AL001 Phase 2 Open-Label Study in Frontotemporal Dementia at the 2020 Alzheimer’s Association International Conference

Alector Announces Publication of Preclinical and Phase 1 Data Validating Potential of AL002, a TREM2 Activating Antibody for the Treatment of Alzheimer’s Disease, in The Journal of Experimental Medicine

Alector to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

Alector Reports 2020 First Quarter Financial Results and Business Highlights

Alector to Present at the Bank of America Securities Virtual Health Care Conference